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ABSTRACT 
Objective: Synthesize new series of 7-hydroxy-4-methylcoumarin and 7-alkoxy-4-methylcoumarin derivatives featuring thiosemicarbazone or 
thiazolidin-4-one moieties and to evaluate their antimicrobial activity against two strains of Gram-positive bacteria (Staphylococcus aureus and 
Bacillus subtilis), two Gram-negative bacteria (Escherichia Coli and Pseudomonas aeruginosa), and Candida albicans. 
Methods: Preparation of the new coumarin derivatives was done by adopting Pechmann condensation and attaching different isothiocyanates to 
give coumarin-thiosemicarbazone hybrids. Thiosemicarbazones were cyclized into thiazolidine-4-ones using chloroacetic acid or diethyl bromo 
malonate.  
Results: Compounds VIb, Xb, XIVb, and XVc gave the highest inhibition zones (>20 mm) against Staphylococcus aureus. Their MIC (minimum 
inhibitory concentration) values ranging from 0.19-0.36 µg/ml were better than the reference drug tobramycin with MIC= 2µg/ml.  
Conclusion: The newly synthesized compounds with the 7-hydroxyl group showed better antimicrobial activity than those with the 7-alkoxy 
groups. 
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INTRODUCTION 
Coumarins are a class of naturally occurring compounds, found in 
variable levels throughout the plant kingdom. Some important 
coumarins were isolated from microorganisms such as novobiocin 1 
from Streptomyces species. They are used by plants as pesticides to 
protect themselves from predators [1, 2]. Applications of coumarins 
range from additives in food, perfumes, and cosmetics, to the 
preparation of insecticides, optical brighteners, and tunable laser 
dyes [3]. Today coumarins are very important in the pharmaceutical 
field due to their wide occurrence, and versatile pharmacological 
activity associated with low toxicity profile such as antimicrobial, 
anticoagulant, antioxidant, and anticancer activities [1-4]. Coumarin 
itself was reported to have an immunostimulatory activity on 
macrophages and other cells of the immune system. This results in 
the use of coumarin in chronic infections such as chronic brucellosis, 
mycoplasmosis, toxoplasmosis, and Q fever [1].  
Novobiocin 1 and clorobiocin 2 are DNA-gyrase inhibitors having a 
strong activity against Gram-positive bacteria especially methicillin-
resistant strains of Staphylococcus aureus (MRSA) [fig. 1]. But due to 
limitations regarding solubility, toxicity, and development of 
resistance, efforts were dedicated to designing an effective, orally 
bioavailable antimicrobial agents bearing coumarin nucleus [4]. 
Over the past decades, thiosemicarbazones attracted researchers for 
thorough investigation due to their diverse biological activity. They 
were known to have antiviral [5], antibacterial [6], anti-tuberculosis 
[7], anti-Trypanosoma cruzi [8] and antineoplastic activities [9]. 
This wide range of pharmacological activities was attributed to the 
strong chelating ability of thiosemicarbazones ligand to biologically 
important metals like iron, copper, nickel, and to their reductive 
capacities [10]. In 2011, Patil et al. reported the synthesis of new 
coumarin-8-yl-thiosemicarbazones 3, 4 that possessed potential 
antibacterial activity against S. aureus, S. typhi, and E. coli [11]. Also, 
thiosemicarbazones act as key intermediates in the preparation of 
important compounds that in turn have a potential antimicrobial 
activity such as thiazolidin-4-one derivatives. Thiazolidine-4-one 
derivative 5 possessed comparable activity to ampicillin and 
chloramphenicol at a concentration 25 µg/ml [12].  
Also, 4-methylcoumarin-thiazolidine-4-one hybrids 6 and 7 were 
reported to exhibit good antimicrobial activity; the former 
compound had comparable activity to ciprofloxacin and griseofulvin 
at 10 µg/ml [13, 14] and the later possessed potent antifungal 
activity with MIC value of 0.10 µg/ml [15] (fig. 1).  
Thus, the purpose of this work was to study the effect of hybridizing 
7-hydroxy-4-methylcoumarin and their 7-alkoxy analogs with 
different N4-substituted thiosemicarbazone that were cyclized into 
the C5-substituted-thiazolidine-4-one ring (fig. 2). The antimicrobial 
activity of new compounds VI-XVII was evaluated. 
MATERIALS AND METHODS 
Starting materials and reagents were purchased from Sigma-Aldrich 
and were used without further purification. Melting points were 
determined using Electrothermal capillary melting point apparatus 
9100 and were uncorrected. IR spectra were recorded on a 
Shimadzu FT-IR Affinity-1 Spectrophotometer, using KBr discs at 
MUST University. 1H-NMR and 13C-NMR spectra were recorded in δ 
scale given in ppm and performed on a JEOL ECA 300, 400 MHz 
spectrometer using CDCl3 or DMSO as stated, using TMS as an 
internal standard at Cairo University.  
Mass spectra were performed on Shimadzu Qp-2010 plus (70 eV) 
spectrometer at Cairo and Azhar University. Elemental analysis was 
performed at Azhar University. The microorganisms were 
purchased from Microbiological Resources Centre (MIRCEN), 
Faculty of agriculture, Ain-Shams University. 
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Synthesis of 8-Acetyl-7-alkoxy-4-methylcoumarin (IIIa-c): 
General Procedures: The 7-hydroxy Compound II (2.18 g., 0.010 
mol) was stirred in dry acetone with anhydrous K2CO3 (1.5 g., 0.011 
mol) for one hour, then the appropriate alkyl halide (ethyl iodide for 
IIIa, allyl bromide for IIIb, butyl bromide for IIIc) (0.050 mol) was 
added to the solution. The reaction mixture was refluxed for 8 h, 
concentrated and poured onto ice cold water. The solid formed was 
filtered and recrystallized from ethanol.  
8-Acetyl-7-ethoxy-4-methylcoumarin (IIIa): Yield: 98%; m. p: 
123-124 ᵒC; IR (ṽ max, cm-1): 3084 (CH, Ar), 2980 (CH, aliphatic), 











































Novobiocin (1): R1= CH3, R2= NH2














Fig. 1: Some reported lead antimicrobials having the main pharmacophores under investigation 
 
 
Fig. 2: Design strategy for the new compounds VI-XVII 
 
8-Acetyl-7-allyloxy-4-methylchromen-2-one (IIIb): Yield: 97%; 
m. p: 118-120 ᵒC; IR (ṽ max, cm-1): 3088 (CH, Ar), 2991 (CH, 
aliphatic), 1724 (CH3-C-C=O), 1703 (C=O, α–pyrone), 1598 (C=C, Ar 
and allyl); MS (m/z): 258. 
8-Acetyl-7-butoxy-4-methylcoumarin (IIIc): Yield: 97%; m. p: 89-
90 ᵒC; IR (ṽ max, cm-1): 3084 (CH, Ar), 2987 (CH, aliphatic), 1716 
(CH3-C-C=O), 1703 (C=O, α–pyrone), 1597 (C=C, Ar). 
Synthesis of 8-Acetyl-7-substituted-4-methylcoumarin-hydrazones 
(IV and Va-Vc): General Procedures: 8-Acetyl-7-substituted-4-
methylcoumarins II and IIIa-c (0.010 mol) were dissolved in 25 ml 
ethanol, poured onto hydrazine hydrate 99% (0.55 ml, 0.011 mole) and 
heated under reflux for 2 h. Light yellow crystals of the hydrazones were 
separated, collected by filtration and washed with water. 
8-Acetyl-7-hydroxy-4-methylcoumarin-hydrazone (IV): Yield= 
68%; m. p: 205-208 ᵒC; IR (ṽ max, cm-1): 3468 (OH), 3381 and 3381 
(NH2), 2926 (CH, aliphatic), 1697 (C=O, α–pyrone), 1558 (C=C, Ar). 
8-Acetyl-7-ethoxy-4-methylcoumarin-hydrazone (Va): Yield= 
92%; m. p: 138-140 ᵒC; IR (ṽ max, cm-1): 3412 and 3234 (NH2), 3051 
(CH, Ar), 2981 (CH, aliphatic), 1708 (C=O, α–pyrone), 1597 (C=C, Ar). 
8-Acetyl-7-allyloxy-4-methylcoumarin-hydrazone (Vb): Yield= 
99%; m. p: 84-86 ᵒC; IR (ṽ max, cm-1): 3379 and 3226 (NH2), 3088 
(CH, Ar), 2968 (CH, aliphatic), 1724 (C=O, α–pyrone), 1597 (C=C, 
Ar); MS (m/z):247. 
8-Acetyl-7-butoxy-4-methylcoumarin-hydrazone (Vc): Yield= 
60%; m. p: 146-148 ᵒC; IR (ṽ max, cm-1): 3390 (NH), 3084 (CH, Ar), 
2987 (CH, aliphatic), 1707 (C=O, α–pyrone), 1622 (C=N, imine), 
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1597 (C=C, Ar); Anal. Calc: C, 66.65; H, 6.99; N, 9.72; Found: C, 66.91; 
H, 7.12; N, 9.89. 
Synthesis of thiosemicarbazones (VI-IX): General Procedures: 
The hydrazones IV and Va-Vc (0.005 mol) were dissolved in the 
minimal amount of dimethyl formamide diluted with 20 ml ethanol 
then the appropriate isothiocyanate derivative (0.005 mol) was 
added. The solution was refluxed for 8 h then diluted with iced cold 
water. A crystalline solid was separated, collected, and recrystallize 
from ethanol. 
8-Acetyl-7-hydroxy-4-methylcoumarin-4-benzyl 
thiosemicarbazone (VIa): Yield= 74.9%; m. p: 220-222 ᵒC; IR (ṽ 
max, cm-1): 3466 (OH), 3406 and 3292 (2NH), 3040 (CH, Ar), 1720 
(C=O, α–pyrone), 1616 (C=N imine), 1597 (C=C, Ar); 1HNMR (400 
MHz, CDCl3): δ= 1.54 (s, 3H, N=C-CH3), 2.45 (s, 3H,-C=C-CH3), 4.56 (d, 
2H,-CH2-Ph, J=4 Hz), 6.16 (s, 1H, 3-H), 6.94 (d, 1H, 6-H, J= 8 Hz), 7.29-
7.32 (m, 5H, Ar), 7.52 (d, 1H, 5-H, J=8 Hz), 6.12 (s, 1H, OH, D2O 
exchangeable), 9.42 and 7.97 (s, 2H, 2NH, D2O exchangeable); MS 
(m/z): 381, 383; Anal calcd. C, 62.97; H, 5.02; N, 11.02; found: C, 
63.14; H, 5.09; N, 11.17. 
8-Acetyl-7-hydroxy-4-methylcoumarin-4-benzoyl 
thiosemicarbazone (VIb): Yield= 73%; m. p: 220-223 ᵒC; IR (ṽ max, 
cm-1): 3547 (OH), 3234 and 3473 (2NH), 3120 (CH, Ar), 1728 and 
1662 (2C=O), 1635 (C=N imine), 1598 (C=C, Ar); 1HNMR (300 MHz, 
CDCl3): δ= 2.4 (s, 3H, N=C-CH3), 2.7 (s, 3H, C4-CH3), 6.15 (s,1H, H-3 of 
coumarin), 7.03 (d, 1H, C6-H of coumarin, J= 9 Hz), 7.59 (t, t, 2H, C3-
H, C5-H of phenyl, J=6 Hz), 7.68 (d, d, 2H, C2-H,C6-H of phenyl, J=6 
Hz), 7.93 (d, 1H, C6-H of coumarin), 9.29 and 13.85 (s, 2H, 2NH, D2O 
exchangeable); MS (m/z): 395; Anal calcd. C, 60.75; H, 4.33; N, 10.63; 
found: C, 60.89; H, 4.38; N, 10.79. 
8-Acetyl-7-ethoxy-4-methylcoumarin-4-cyclohexyl 
thiosemicarbazone (VIIa): Yield= 92%; m. p: 190-191 ᵒC; IR (ṽ 
max, cm-1): 3244 and 3142 (2NH), 3014 (CH, Ar), 2931 (CH, 
aliphatic), 1728 (C=O), 1629 (C=N imine), 1597 (C=C, Ar); 1HNMR 
(300 MHz, CDCl3): δ= 1.47 (t, 3H, CH3-, J=6 Hz), 2.31 (s,3H, N=C-CH3), 
2.37-2.43 (m, 6H,C3-2H,C4-2H, and C5-2H of cyclohexyl), 2.71 (s, 3H, 
C4-CH3), 2.82-2.89 (m, 4H, C2-2H, C6-2H of cyclohexyl), 3.22 (m, 1H, 
C1-H of cyclohexyl), 4.23 (q, 2H,-CH2-O, J=6 Hz), 5.99 (s,1H, NH, D2O 
exchangeable), 6.17 (s,1H, C3-H), 6.94 (d,1H, C6-H, J=9 Hz), 7.64 
(d,1H, C5-H, J=9); MS (m/z): 401; Anal calcd. C, 62.82; H, 6.78; N, 
10.47; found: C, 63.04; H, 6.86; N, 10.61. 
8-Acetyl-7-ethoxy-4-methylcoumarin-4-phenyl 
thiosemicarbazone (VIIb): Yield= 98%; m. p: 110-112 ᵒC; IR (ṽ max, 
cm-1): 3444 and 3460 (2NH), 3055 (CH, Ar), 2981 (CH, aliphatic), 1734 
(C=O), 1597 (C=C, Ar), 1174 (C-O ether); 1HNMR (300 MHz, CDCl3): δ= 
1.45 (t, 3H, CH3-, J=6 Hz), 2.36 (s, 3H, N=C-CH3), 2.42,(s, 3H, 4-CH3), 
4.22 (m, 2H,-CH2-O, J=6 Hz), 6.20 (s, 1H, C3-H), 6.95 (d, 1H, C6-H, J=9 
Hz), 7.32 (t, 1H, C4-H of phenyl), 7.37 (d, 2H, C2-H, C6-H of phenyl, J=9 
Hz), 7.65 (d, 2H, C3-H, C5-H of phenyl, J=9 Hz), 7.69 (d,1H, C5-H), 9.84 
(s,1H, NH, D2O exchangeable), 10.46 (s,1H, OH, D2O exchangeable); 
13CNMR (400 MHz, CDCl3): δ= 14.6 (CH3-), 18.6 (CH3-), 23.2 (CH3-), 
32.6 (C5 of thiazolidin-4-one), 64.5 (-CH2-O), 107.9 (C3 of coumarin), 
108.3 (C8 of coumarin), 112.0 (C6 of coumarin), 117.3 (C10 of 
coumarin), 125.0 (C2, C6 of phenyl), 127.3 (C4 of phenyl), 128.2 (C3, 
C5 of phenyl), 129.1 (C5 of coumarin), 134.5 (C1 of phenyl), 151.9 (C9 
of coumarin), 152.1 (C4 of coumarin), 157.4 (C7 of coumarin), 159.2 
(C2 of coumarin), 160.3 (C2 of thiazolidin-4-one), 161.1 (-C=N-), 171.5 
(-C=O of thiazolidin-4-one); MS (m/z): 395; Anal calcd. C, 63.78; H, 
5.35; N, 10.63; found: C, 63.97; H, 5.42; N, 10.88. 
8-Acetyl-7-ethoxy-4-methylcoumarin-4-(4-methoxyphenyl) 
thiosemicarbazone (VIIc): Yield= 99%; m. p: 206-208 ᵒC; IR (ṽ 
max, cm-1): 3319 and 3278 (2NH), 3062 (CH, Ar), 2837-2981 (CH, 
aliphatic), 1722 (C=O), 1595 (C=C, Ar), 1182 (C-O ether); 1HNMR 
(300 MHz, CDCl3): δ= 1.45 (t, 3H, CH3-, J=8 Hz), 2.35 (s, 3H, CH3-), 
2.45 (s, 3H, C4-CH3), 3.83 (s, 3H, CH3-O-Ph), 4.17-4.24 (m, 2H,-CH2-O, 
J=8 Hz), 6.20 (s, 1H, 3-H), 6.88-6.97 (m, 4H, Ar), 7.48 (d, 1H, C6-H, 
J=8 Hz), 7.67 (d,1H, C5-H, J=8 Hz), 8.27 and 9.19 (s,2H, 2NH, D2O 
exchangeable); MS (m/z): 426; Anal calcd. C, 62.10; H, 5.45; N, 9.88; 
found: C, 62.42; H, 5.51; N, 10.03. 
8-Acetyl-7-allyloxy-4-methylcoumarin-4-cyclohexyl 
thiosemicarbazone (VIIIa): Yield= 96%; m. p: 206-208 ᵒC; IR (ṽ 
max, cm-1): 3354 and 3244 (2NH), 3053 (CH, Ar), 2962 (CH, 
aliphatic), 1724 (C=O), 1597 (C=C, Ar); 1HNMR (400 MHz, CDCl3): δ= 
1.59 (s, 3H, N=C-CH3), 1.88-1.92 (m, C3-H, C4-H, and C5-H of 
cyclohexyl), 2.11-2.17 (m C2-H, C6-H of cyclohexyl), 2.37 (m, 1H, C1-
H of cyclohexyl), 2.42 (s, 3H, C4-CH3), 4.77 (d, 2H,–CH2-O, J= 8 Hz), 
5.23 and 5.31 (d, d, 2H, CH2=, J=8 Hz), 5.96-6.00 (m, 1H, =CH–), 6.12 
(s, 1H, C3-H), 6.92 (d, 1H, C6-H, J=8 Hz), 7.53 (d, 1H, C5-H, J=8 Hz); 
MS (m/z): 413; Anal calcd. C, 63.90; H, 5.92; N, 10.16; found: C, 
64.08; H, 5.97; N, 10.31. 
8-Acetyl-7-allyloxy-4-methylcoumarin-4-benzyl 
thiosemicarbazone (VIIIb): Yield= 84%; m. p: 102-104ᵒC; IR (ṽ 
max, cm-1): 3419 and 3367 (2NH), 3084 (CH, Ar), 2980 (CH, 
aliphatic), 1732 (C=O), 1598 (C=C, Ar); 1HNMR (400 MHz, CDCl3): δ= 
2.26 (s, 3H, N=C-CH3), 2.43 (s, 3H, C4-CH3), 4.50 (d, 2H,-CH2-O-, J= 8 
Hz), 4.76 (d, 2H, Ph-CH2-), 5.33 and 5.36 (d, d, 2H, CH2=, J=8 Hz), 
5.95-6.04 (m, 1H, =CH–), 6.20 (s, 1H, C3-H), 6.95 (d, 1H, C6-H, J=8 
Hz), 7.25-7.40 (m, 5H, Ar), 7.54 (d, 1H, C5-H, J=8 Hz), 8.2 and 8.8 (s, 
2H, 2NH, D2O exchangeable); 13CNMR (400 MHz, CDCl3): δ= 18.7 
(CH3-), 23.5 (-CH3), 48.4 (-CH2-ph), 69.7 (-CH2-O-), 109.0 (C3 of 
coumarin), 110.0 (C8 of coumarin), 112.3 (C6 of coumarin), 114.7 
(CH2=), 118.7 (C10 of coumarin), 125.7 (C4 of phenyl), 127.4 (C2, C6 
of phenyl), 127.9 (C3, C5 of phenyl), 128.7 (C5 of coumarin), 131.6 
(=CH-), 137.5 (C1 of phenyl), 142.9 (C9 of coumarin), 151.1 (C4 of 
coumarin), 152.1 (-C=N-), 157.1 (C2 of coumarin), 159.8 (C7 of 
coumarin), 177.6 (-C=S); MS (m/z): 421; Anal calcd: C, 65.54; H, 5.5; 
N, 9. 97; found: C, 65.73; H, 5.54; N, 10.08. 
8-Acetyl-7-allyloxy-4-methylcoumarin-4-(4-methoxyphenyl) 
thiosemicarbazone (VIIIc): Yield= 95%; m. p: 186-187 ᵒC; IR (ṽ 
max, cm-1): 3319 and 3278 (2NH), 3032, (CH, Ar), 2970 (CH, 
aliphatic), 1720 (C=O), 1597 (C=C, Ar); 1HNMR (400 MHz, CDCl3): δ= 
2.29 (s, 3H,-N=C-CH3), 2.43 (s, 3H, C4-CH3), 3.81 (s, 3H, CH3-O-Ph-), 
4.69 (d, 2H,-CH2-O-, J= 8 Hz), 5.37 (d, 2H, CH2=, J=8 Hz), 6.02 (m, 1H, 
=CH–), 6.18 (s, 1H, C3-H), 6.88-6.97 (m, 4H, phenyl), 7.47-7.51 (d, 
2H, C5-H, C6-H, J=8 Hz), 8.8 and 9.10 (s, 2H, 2NH, D2O 
exchangeable); MS (m/z): 437, 438 (M+1); Anal calcd. C 63.14; H 
5.30; N 9.60; found: C 63.29; H 5.32; N 9.67. 
8-Acetyl-7-butoxy-4-methylcoumarin-4-ethyl 
thiosemicarbazone (IXa): Yield= 99%; m. p: 170-169 ᵒC; IR (ṽ max, 
cm-1): 3448 and 3220 (2NH), 2954 (CH, aliphatic), 1732 (C=O), 1598 
(C=C, Ar); 1HNMR (400 MHz, CDCl3): δ= 0.98 (t, 3H, CH3-, J= 8 Hz), 
1.25 (t, 3H, CH3-, J= 8 Hz), 1.47 (m, 2H,-CH2-, J= 8 Hz), 1.78 (m, 2H,-
CH2-, J= 8 Hz), 2.22 (s, 3H,-N=C-CH3), 2.43 (s, 3H, C4-CH3), 3.72 (q, 
2H,-CH2-N-, J= 8 Hz), 4.09 (t, 2H,-CH2-O-, J= 8 Hz), 6.17 (s, 1H, C3-H), 
6.92 (d,1H, C6-H), 7.58 (d, H, C5-H, J= 8 Hz), 8.64 (s, 1H, NH, D2O 
exchangeable); MS (m/z): 375; Anal calcd. C, 60.78, H, 6.71, N, 11.19; 
found: C, 60.91; H, 6.82; N, 11.31. 
8-Acetyl-7-butoxy-4-methylcoumarin-4-benzyl 
thiosemicarbazone (IXb): Yield= 99%; m. p: 140-142 ᵒC; IR (ṽ max, 
cm-1): 3419 and 3253 (2NH), 3088 (CH, Ar), 2960 (CH, aliphatic), 
1732 (C=O), 1602 (C=N imine), 1550 (C=C, Ar); 1HNMR (400 MHz, 
CDCl3): δ= 0.96 (t, 3H, CH3-, J= 8 Hz), 1.44 (m, 2H,-CH2-, J= 8 Hz), 1.74 
(m, 2H,-CH2-, J= 8 Hz), 2.24 (s, 3H, N=C-CH3), 2.40 (s, 3H, C4-CH3), 
4.05 (t, 2H,-CH2-O, J= 8 Hz), 4.92 (s, 2H,-CH2-ph), 6.15 (s, 1H, C3-H), 
6.88 (d,1H, C6-H, J= 8 Hz), 7.26-7.37 (5H, phenyl), 7.55 (d, H, C5-H, J= 
8 Hz), 8.79 (s, 1H, NH, D2O exchangeable) MS (m/z): 437; Anal calcd. 
C, 65.88; H, 6.22; N, 9.60; found: C, 65.98; H, 6.28; N, 9.72. 
Synthesis of thiazolidine-4-ones (X-XIII): General procedures: 
The thiosemicarbazones VI-IX (0.005 mol) were reacted with 
chloroacetic acid (0.00505 mol, 0.618 g) in freshly fused sodium 
acetate (0.00505 mol, 0.414 g) and 30 ml ethanol. The solution was 
refluxed for 8 h, concentrated, and diluted with ice cold water. A 
crystalline solid was separated, collected, and recrystallized from 
ethanol. 
3-Benzyl-2-{[1-(7-hydroxy-4-methylcoumarin-8-yl)-ethylidene] 
-hydrazono}-thiazolidin-4-one (Xa): Yield= 67%; m. p: 144-146 
ᵒC; IR (ṽ max, cm-1): 3444 (OH), 3089 (CH, Ar), 2924 (CH, aliphatic), 
1720 and1687 (2C=O), 1629 (C=N imine), 1597 (C=C, Ar); 1HNMR 
(400 MHz, CDCl3): δ= 1.56 (s, 3H, 4-CH3), 2.46 (s, 3H, N=C-CH3), 2.85 
(s, 2H, S-CH2-CO), 4.57 (s, 2H, Benzyl CH2), 6.16 (s, 1H, C3-H), 6.95 
(d,1H, C6-H), 7.35 (m, 5H, Ar), 7.62 (d, 2H, 4, C5-H, J= 8 Hz); MS 
Abdelnaby et al. 
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(m/z): 421; Anal calcd. C 62.69; H 4.54; N 9.97; found: C 62.78; H 
4.51, N 10.08. 
3-Benzoyl-2-{[1-(7-hydroxy-4-methylcoumarin-8-yl)-
ethylidene]-hydrazono}-thiazolidin-4-one (Xb): Yield= 75%; m. 
p: 128-130 ᵒC; IR (ṽ max, cm-1): 3446 (OH), 3066 (CH, Ar), 2980 (CH, 
aliphatic), 1728 and1670 (2C=O), 1624 (C=N imine), 1598 (C=C, Ar); 
1HNMR (400 MHz, CDCl3): δ= 2.44 (s, 3H, 4-CH3), 2.84 (s, 3H, N=C-
CH3), 3.83 (s, 2H, S-CH2-CO), 6.19 (s, 1H, C3-H), 6.95 (d,1H, C6-H, J=8 
Hz), 7.50-7.62 (m, 3H, C3, C4, C5-H of phenyl), 7.70 (d,1H, C5-H, J=8 
Hz); MS (m/z): 435; Anal calcd: C 60.68; H 3.93; N 9.65; found: C, 
60.74; H, 3.96; N, 9.77. 
3-Cyclohexyl-2-{[1-(7-ethoxy-4-methylcoumarin-8-yl)-
ethylidene]-hydrazono}-thiazolidin-4-one (XIa): Yield= 56%; m. 
p: 246-247 ᵒC; IR (ṽ max, cm-1): 3059 (CH, Ar), 2978 (CH, aliphatic), 
1716 (C=O), 1620 (C=N imine), 1597 (C=C, Ar); 1HNMR (400 MHz, 
DMSO): δ= 1.08 (t, 3H, CH3-CH2-O), 2.07 (s, 3H, 4-CH3), 2.16 (s, 3H, 
N=C-CH3), 2.27 (t, 4H, 2andC6-H of cyclohexyl), 3.65 (m, 1H, C1-H of 
cyclohexyl), 3.68 (s, 2H, S-CH2-CO), 3.93 (t, 2H, CH3-CH2-O, J= 8 Hz), 
5.98 (s, 1H, C3-H), 6.91 (d,1H, C6-H, J=8 Hz), 7.52 (d, 2H, 4, C5-H, J=8 
Hz); MS (m/z): 441; Anal calcd: C, 62.56; H, 6.16; N, 9.52; found: C, 
62.67; H, 6.30; N, 9.61. 
2-{[1-(7-Ethoxy-4-methylcoumarin-8-yl)-ethylidene]-
hydrazono}-3-phenyl-thiazolidin-4-one (XIb): Yield= 89%; m. p: 
257-260 ᵒC; IR (ṽ max, cm-1): 3064 (CH, Ar), 2980 (CH, aliphatic), 
1732 and 1720 (2C=O), 1597 (C=C, Ar); 1HNMR (400 MHz, CDCl3): 
δ= 1.32 (t, 3H, CH3-CH2-O, J=8 Hz), 2.23 (s, 3H, C4-CH3), 2.39 (s, 3H, 
N=C-CH3), 3.92 (m, 4H, S-CH2-CO and CH3-CH2-O), 6.10 (s, 1H, C3-H), 
6.71 (d,1H, C6-H, J=8 Hz), 6.95 (d, 2H, C2, C6-H of phenyl, J= Hz), 7.11 (m, 
3H, C3,4,C5-H of phenyl), 7.41 (d, 2H, 4, C5-H, J=8 Hz); MS (m/z): 435; 
Anal calcd. C, 63.43; H, 4.86; N, 9.65; found: C 63.65; H 4.92; N 9.78. 
2-{[1-(7-Ethoxy-4-methylcoumarin-8-yl)-ethylidene]-
hydrazono}-3-(4-methoxy-phenyl)-thiazolidin-4-one (XIc): 
Yield= 89%; m. p: 170-172 ᵒC; IR (ṽ max, cm-1): 2980 (CH, aliphatic), 
1718 (C=O), 1624 (C=N imine), 1598 (C=C); 1HNMR (400 MHz, 
CDCl3): δ= 1.34 (t, 3H, CH3-CH2-O, J=8 Hz), 2.19 (s, 3H, 4-CH3), 2.41 
(s, 3H, N=C-CH3), 3.75 (s, 3H, CH3-O-Ph), 3.88 (s, 2H, S-CH2-CO), 4.05 
(q, 2H, CH3-CH2-O), 6.10 (s, 1H, C3-H), 6.87 (d,1H, C6-H, J=8 Hz), 
6.89-7.39 (m, 5H, Ar), 7.55 (d, 2H, 4, C5-H, J=8 Hz),; MS (m/z): 465; 
Anal calcd: C, 64.13; H, 5.16; N, 9.35; found: C, 64.28; H, 5.20; N, 9.43. 
3-Cyclohexyl-2-{[1-(7-allyloxy-4-methylcoumarin-8-yl)-
ethylidene]-hydrazono}-thiazolidin-4-one (XIIa): Yield= 91%; m. 
p: 114-116 ᵒC; IR (ṽ max, cm-1): 3080 (CH, Ar and allyl), 2962 (CH, 
aliphatic), 1720 (C=O), 1618 (C=N imine), 1598 (C=C, Ar, allyl); 
1HNMR (400 MHz, CDCl3): δ= 2.10 (s, 3H, C4-CH3), 2.17 (s, 3H, N=C-
CH3), 3.45 (s, 2H, S-CH2-C=O), 3.74-3.82 (m, 1H, C1-H of cyclohexyl), 
4.40 (d, 2H, CH2=CH-CH2-O-, J= 8 Hz), 5.01-5.15 (d, d, 2H, CH2=CH-
CH2-O-, J=8 Hz), 5.72-5.76 (m, 1H, CH2=CH–CH2-O-), 6.69 (d, 1H, C6-
H, J=8 Hz), 7.31 (d, 1H, C5-H, J=8 Hz); MS (m/z): 453; Anal calcd.: C, 
63.56; H, 6.00; N, 9. 26; found, C, 63.78; H, 6.13; N, 9.49. 
3-Benzyl-2-{[1-(7-allyloxy-4-methylcoumarin-8-yl)-ethylidene]-
hydrazono}-thiazolidin-4-one (XIIb): Yield= 81%; m. p: 182-184 
ᵒC; IR (ṽ max, cm-1): 3005-3086 (CH, Ar and allyl), 2981 (CH, 
aliphatic), 1728 and 1710 (2C=O), 1622 (C=N imine), 1600 (C=C, Ar, 
allyl); 1HNMR (400 MHz, CDCl3): δ= 2.35 (s, 3H, C4-CH3), 2.41 (s, 3H, 
N=C-CH3), 3.77 (s, 2H, S-CH2-C=O), 4.56 (d, 2H, CH2=CH-CH2-O-, J= 8 
Hz), 4.68 (d, 2H, Ph-CH2-NH-), 5.31 and 5.37 (d, d, 2H, CH2=CH-CH2-
O-, J=8 Hz), 5.92-6.05 (m, 1H, CH2=CH–CH2-O-), 6.16 (s, 1H, C3-H), 
6.88-7.56 (m, 5H, Ar); MS (m/z): 461; Anal calcd. C, 65.06; H, 5.02; N, 
9.10; found: C, 65.24; H, 5.11; N, 9.31. 
3-(4-Methoxy-phenyl)-2-{[1-(7-allyloxy-4-methylcoumarin-8-
yl)-ethylidene]-hydrazono}-thiazolidin-4-one (XIIc): Yield= 
97%; m. p: 200-202 ᵒC; IR (ṽ max, cm-1): 3057 (CH, Ar and allyl), 
2966 (CH, aliphatic), 1724 (C=O), 1616 (C=N imine), 1597 (C=C, Ar, 
allyl); 1HNMR (400 MHz, CDCl3): δ= 2.3 (s, 3H, C4-CH3), 2.40 (s, 3H, 
N=C-CH3), 3.74 (s, 3H, methoxy), 3.89 (s, 2H, S-CH2-C=O), 4.50 (d, 2H, 
CH2=CH-CH2-O-, J=8 Hz), 5.20-5.31 (d, d, 2H, CH2=CH-CH2-O-), 5.85-
5.94 (m, 1H, CH2=CH–CH2), 6.09 (s, 1H, C3-H), 6.75 (d, 2H, C3 and C5 
of phenyl, J= 8 Hz), 6.72 (d, 1H, C6-H, J=8 Hz), 6.85 (d, 2H, C2 and C6 
of phenyl, J= 8 Hz), 7.42 (d, 1H, C5-H, J=8 Hz); MS (m/z): 477; Anal 
calcd. C, 62.88; H, 4.85; N, 8.80; found: C, 63.01; H, 4.89; N, 8.92. 
2-{[1-(7-Butoxy-4-methylcoumarin-8-yl)-ethylidene]-
hydrazono}-3-ethyl-thiazolidin-4-one (XIIIa): Yield= 99%; m. p: 
201-203 ᵒC; IR (ṽ max, cm-1): 3080 (CH, Ar), 2953 (CH, aliphatic), 
1737 and 1722 (2C=O), 1571 (C=C, Ar); 1HNMR (400 MHz, CDCl3): 
δ= 0.96 (t, 3H, CH3-(CH2)3-O, J= 8 Hz), 1.34 (t, 3H, CH3-CH2-N, J= 8 
Hz), 1.48 (m, 2H, CH3-CH2-(CH2)2-O, J= 8 Hz), 1.79 (m, 2H, CH3-CH2-
CH2-CH2-O, J= 8 Hz), 2.36 (s, 3H, C4-CH3), 2.41 (s, 3H,-N=C-CH3), 3.73 
(s, 2H, S-CH2-C=O), 3.94 (t,2H, CH3-CH2-N-, J= 8 Hz), 4.09 (t, 2H, CH3-
CH2-CH2-CH2-O, J= 8 Hz), 6.14 (s, 1H, C3-H), 6.90 (d,1H, C6-H, J= 8 
Hz), 7.54 (d, H, C5-H, J= 8 Hz); MS (m/z): 415; Anal calcd. C, 60.70; H, 
6.06; N, 10.11; found: C, 60.37; H, 5.38; N, 10.69. 
3-Benzyl-2-{[1-(7-butoxy-4-methylcoumarin-8-yl)-ethylidene]-
hydrazono}-thiazolidin-4-one (XIIIb): Yield= 91%; m. p: 180-182 
ᵒC; IR (ṽ max, cm-1): 3082 (CH, Ar), 2939 (CH, aliphatic), 1720 (C=O), 
1589 (C=C, Ar); 1HNMR (400 MHz, CDCl3): δ= 0.91 (t, 3H, CH3-(CH2)3-
O, J= 8 Hz), 1.39 (m, 2H, CH3-CH2-(CH2)2-O, J= 8 Hz), 1.68 (m, 2H, 
CH3-CH2-CH2-CH2-O, J= 8 Hz), 2.39 (s, 3H, C4-CH3), 2.43 (s, 3H, N=C-
CH3), 3.76 (s, 2H, S-CH2-C=O), 3.91-3.95 (t, 2H, CH3-CH2-CH2-CH2-O, 
J= 8 Hz), 4.54 (s, 2H, CH2-N-), 6.12 (s, 1H, C3-H), 6.90 (d,1H, C6-H, J= 
8 Hz), 7.05 (m, 3H, C2,6,4 of phenyl), 7.15 (t, 2H, C3,5 of phenyl), 
7.55 (d, H, C5-H); MS (m/z): 474; Anal calcd. C, 65.39; H, 5.70; N, 
8.80; found: C, 65.62; H, 5.78; N, 8.91. 
Synthesis of thiazolidine-4-ones (XIV-XVII): General 
procedures: The thiosemicarbazones V-VIII (0.005 mol) were 
reacted with diethyl bromo malonate (0.00505 mol, 1.207 g) in 
freshly fused sodium acetate (0.00505 mol, 0.41400 g) and 30 ml 
ethanol. The solution was refluxed for 8 h, concentrated, and diluted 
with ice cold water. A crystalline solid was separated, collected, and 
recrystallized from ethanol. 
3-Benzyl-2-{[1-(7-hydroxy-4-methylcoumarin-8-yl)-
ethylidene]-hydrazono}-thiazolidin-4-one-5-carboxylic acid 
ethyl ester (XIVa): Yield= 91%; m. p: 137 ᵒC; IR (ṽ max, cm-1): 3088 
(CH, Ar), 2981 (CH, aliphatic), 1737 and 1724 (2C=O), 1595 (C=C, 
Ar); 1HNMR (400 MHz, CDCl3): δ= 2.37 (s, 3H, C4-CH3), 2.45 (t, 3H, 
CH3-), 2.79 (s, 3H,-N=C-CH3), 4.42-4.91 (m, 4H, 2CH2-of benzyl and 
ethyl), 5.1 (s, 2H, S-CH2-C=O), 6.30 (s, 1H, C3-H), 6.95 (d,1H, C6-H, J= 
8 Hz), 7.28-7.75 (m, 6H, Ar); MS (m/z): 493; Anal calcd. C, 60.84; H, 
4.70; N, 8.51; found: C, 60.47; H, 4.89; N, 8.91. 
3-Benzoyl-2-{[1-(7-hydroxy-4-methylcoumarin-8-yl)-
ethylidene]-hydrazono}-thiazolidin-4-one-5-carboxylic acid 
ethyl ester (XIVb): Yield= 94%; m. p: 135 ᵒC; IR (ṽ max, cm-1): 3066 
(CH, Ar), 2933 (CH, aliphatic), 1732 and 1724 (2C=O), 1598 (C=C, 
Ar); 1HNMR (400 MHz, CDCl3): δ= 2.44 (t, 3H, CH3-), 2.84 (s, 3H, C4-
CH3), 2.98 (s, 3H, N=C-CH3), 4.23-4.39 (m, 4H, 2CH2-of benzyl and 
ethyl), 6.19 (s, 1H, C3-H), 6.94 (d,1H, C6-H, J= 8 Hz), 7.54-8.09 (m, 
6H, Ar), 7.61 (d, H, C5-H); MS (m/z): 508; Anal calcd. C, 59.16; H, 
4.17; N, 8.28; found: C, 58.73; H, 4.37; N, 8.63. 
3-Cyclohexyl-2-{[1-(7-ethoxy-4-methylcoumarin-8-yl)-
ethylidene]-hydrazono}-thiazolidin-4-one-5-carboxylic acid 
ethyl ester (XVa): Yield= 85%; m. p: 247-248 ᵒC; IR (ṽ max, cm-1): 
3055 (CH, Ar), 2976 (CH, aliphatic), 1720 (C=O), 1598 (C=C, Ar); 
1HNMR (400 MHz, CDCl3): δ= 1.22-1.36 (t, 6H, 2CH3-), 2.00-2.43 (m, 
10H, cyclohexyl), 2.28 (s, 3H, C4-CH3), 2.44 (s, 3H,-N=C-CH3), 4.01 (t, 
2H,-CH2-O), 4.12-4.28 (m, 3H, S-CH-C=O of thiazolidine and-CH2-O of 
ethyl ester), 6.21 (s, 1H, C3-H), 6.99 (d,1H, C6-H), 7.63 (d, H, C5-H); 
MS (m/z): 514; Anal calcd. C, 60.80; H, 6.08; N, 8.18; found: C, 60.55; 
H, 6.37; N, 8.61. 
2-{[1-(7-Ethoxy-4-methylcoumarin-8-yl)-ethylidene]-
hydrazono}-4-oxo-3-phenyl-thiazolidine-5-carboxylic acid ethyl 
ester (XVb): Yield= 86%; m. p: 196-198 ᵒC; IR (ṽ max, cm-1): 2983 
(CH, aliphatic), 1745 and 1730 (2C=O), 1597 (C=C, Ar); 1HNMR (400 
MHz, CDCl3): δ= 1.23-1.38 (m, 6H, 2CH3-), 2.21 (s, 3H, C4-CH3), 2.41 
(s, 3H,-N=C-CH3), 3.85-3.91 (m, 2H,-O-CH2-), 4.19-4.41 (m, 2H,-O-
CH2-), 4.67 (s, 1H, S-CH-C=O), 6.11 (s, 1H, C3-H), 6.68 (s, 1H, C6-H), 
7.05-7.15 (m, 2H, C3-H, C5-H of phenyl), 7.39 (m, 2H, C2-H, C6-H of 
phenyl), 7.54 (s, 1H, C5-H); MS (m/z): 507; Anal calcd. C, 61.53; H, 
4.96; N, 8.28; found: C, 61.32; H, 5.19; N, 8.73. 
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carboxylic acid ethyl ester (XVc): Yield= 75%; m. p: 217-218 ᵒC; IR 
(ṽ max, cm-1): 3062 (CH, Ar), 2981 (CH, aliphatic), 1716 (C=O), 1595 
(C=C, Ar); 1HNMR (400 MHz, CDCl3): δ= 1.18-1.35 (m, 6H, 2CH3-), 
2.28 (s, 3H, C4-CH3), 2.41 (s, 3H, N=C-CH3), 3.31 (s, 3H,-O-CH3), 3.73 
(q, 2H,-O-CH2-), 4.25 (q, 2H, CO-O-CH2-), 4.63 (s, 1H, S-CH-C=O), 6.24 
(s, 1H, C3-H), 6.85 (d, 2H, C3-H, C5-H of phenyl), 6.90 (s, 1H, C6-H), 
7.42 (d, 2H, C3-H, C5-H of phenyl), 7.75 (s, 1H, C5-H); MS (m/z): 537; 
Anal calcd. C, 60.32; H, 5.06; N, 7.82; found: C, 59.95; H, 5.30; N, 8.19. 
2-{[1-(7-Allyloxy-4-methylcoumarin-8-yl)-ethylidene]-
hydrazono}-3-cyclohexyl-4-oxo-thiazolidine-5-carboxylic acid 
ethyl ester (XVIa): Yield= 80%; m. p: 80-82 ᵒC; IR (ṽ max, cm-1): 3055 
(CH, Ar and allyl), 2962 (CH, aliphatic), 1737 and1724 (2C=O), 1620 
(C=N imine), 1597 (C=C, Ar, allyl); 1HNMR (400 MHz, CDCl3): δ= 1.19-
1.42 (m, 9H, C3-2H, C4-2H, C5-2H of cyclohexyl and-CH3 of ethyl), 1.77-
1.87 (m, 4H, C2-2H, C6-2H of cyclohexyl), 2.34 (s, 3H, C4-CH3), 2.42 (s, 
3H, N=C-CH3), 3.40 (s, 1H, C1-H of cyclohexyl), 4.06-4.09 (m, 2H,-CH2-
O), 4.56 (s, 1H, S-CH-C=O), 4.67 (d, 2H,-CH2-O), 5.22-5.42 (m, 2H, 
CH2=), 5.97-6.01 (m, 1H, =CH-), 6.15 (s, 1H, C3-H), 6.91 (d, 1H, C-6, J=8 
Hz), 7.55 (d, 1H, C5-H, J=8 Hz); MS (m/z): 523; Anal calcd. C, 61.70; H, 
5.94; N, 7.99; found C, 61.94; H, 6.01; N, 8.14. 
2-{[1-(7-Allyloxy-4-methylcoumarin-8-yl)-ethylidene]-
hydrazono}-3-4-methoxyphenyl-thiazolidin-4-one-5-carboxylic 
acid ethyl ester (XVIc): Yield= 87%; m. p: 188 ᵒC; IR (ṽ max, cm-1): 
3066 (CH, Ar and allyl), 2968 (CH, aliphatic), 1730 and 1718 (C=O), 
1598 (C=C, Ar, allyl); 1HNMR (400 MHz, CDCl3): δ= 2.35 (s, 3H, C4-
CH3), 2.44 (s, 3H, N=C-CH3), 3.83 (s, 3H, CH3-O-Ph), 4.05-4.12 (m, 
3H,-CH2-O and S-CH-C=O), 4.72 (d, 2H,-CH2-O), 5.35-5.40 (d, d, 2H, 
CH2=), 5.99-6.04 (m, 1H, =CH–), 6.17 (s, 1H, C3-H), 6.92-6.98 (m, 3H, 
C3-H, C5-H of phenyl and C6-H), 7.49 (d, 2H, C2 and C6 of phenyl, J= 
8 Hz), 7.66 (d, 1H, C5-H, J=8 Hz); MS (m/z): 550; Anal calcd. C, 61.19; 
H, 4.95; N, 7.65; found: C, 61.09; H, 5.21; N, 8.08. 
2-{[1-(7-Butoxy-4-methylcoumarin-8-yl)-ethylidene]-
hydrazono}-3-ethyl-thiazolidin-4-one-5-carboxylic acid ethyl 
ester (XVIIa): Yield= 85%; m. p: 224-225 ᵒC; IR (ṽ max, cm-1): 2958 
(CH, aliphatic), 1732 (C=O), 1627 (C=N, imine), 1593 (C=C, Ar); 
1HNMR (400 MHz, CDCl3): δ= 0.96 (t, 3H, CH3-, J= 8 Hz), 1.35-1.38 (m, 
3H, CH3-), 1.43-1.52 (m, 2H,-CH2-), 1.75-1.82 (m, 2H,-CH2-), 2.37 (s, 
3H, C4-CH3), 2.40 (s, 3H, N=C-CH3), 3.50-3.53 (m, 2H,-CH2-N), 4.01 (t, 
2H,-CH2-O), 4.06-H, J= 8 Hz), 7.54 (d, 1H, C5-H, J= 8 Hz); MS (m/z): 
485, 487; Anal calcd. C, 59.12; H, 6.00; N, 8.62; found: C, 58.75; H, 
6.26; N, 9.03. 4.10 (m, 2H,-CH2-O), 4.18 (s, 2H, S-CH-C=O), 6.13 (s, 
1H, C3-H), 6.90 (d,1H, C6- 
3-Benzyl-2-{[1-(7-butoxy-4-methylcoumarin-8-yl)-ethylidene]-
hydrazono}-thiazolidin-4-one-5-carboxylic acid ethyl ester 
(XVIIb): Yield= 93%; m. p: charring; IR (ṽ max, cm-1): 3032 (CH, Ar), 
2958 (CH, aliphatic), 1724 (C=O), 1627 (C=N, imine), 1597 (C=C, Ar); 
1HNMR (400 MHz, CDCl3): δ= 0.95 (t, 3H, CH3-, J= 8 Hz), 1.39-1.48 (m, 
2H,-CH2-), 1.75-1.79 (m, 2H,-CH2-), 2.32 (s, 3H, C4-CH3), 2.40 (s, 3H, 
N=C-CH3), 3.74 (t, 2H,-CH2-O, J= 8 Hz), 4.04-4.07 (m, 3H,-CH2-N-and 
S-CH-), 5.09 (s, 2H, CH2-), 6.12 (s, 1H, C3-H), 6.88 (d,1H, C6-H, J= 8 
Hz), 7.30-7.37 (m, 3H, C2-H,C6-H, and C4-H of phenyl), 7.48 (t, 2H, 
C3-H, C5-H of phenyl), 7.53 (d, H, C5-H); MS (m/z): 549; Anal calcd. 
C, 63.37; H, 5.68; N, 7.65; found: C, 62.97; H, 5.89; N, 7.94. 
Antimicrobial activity  
Sensitivity test  
The agar disc plate method using Hi-Media agar medium was 
employed to study the antimicrobial activity of the synthesized 
compounds with tobramycin as the reference drug. The prepared 
compounds were examined against two strains of Gram-positive 
(Staphylococcus aureus ATCC 25923 and Bacillus subtilis ATCC 
14579), Gram-negative bacteria (Pseudomonas aeruginosa ATCC 
27853 and Escherichia coli ATCC 25922) and Candida albicans ATCC 
10231). Each test compound (50 mg) was dissolved in DMSO 
(dimethyl sulphoxide) (0.5 ml, 100 mg/ml), which was used as a 
sample solution. 6 mm discs were impregnated with 100 mg/ml 
solution of the test compound were placed on the solidified nutrient 
agar medium that had been inoculated with the respective 
microorganism and the Petri dishes were subsequently incubated at 
37 ᵒC for 48 h. Tobramycin was used as reference drugs and DMSO 
as a negative control. Zones of inhibition produced by each 
compound were measured in millimetres [16]. 
Minimum inhibitory concentration test (MIC) 
The agar cup plate method using Hi-Media agar medium was 
employed to study the antibacterial activity against Staphylococcus 
aureus. Each test compound (50 mg) was dissolved in dimethyl 
sulphoxide (100 mg/ml), which was used as a stock solution to carry 
out two-fold dilution technique. The sample size for all the 
compounds was fixed at 0.1 ml. Using a sterilized cork borer, cups 
were scooped out of Agar medium contained in a Petri dish which 
was previously inoculated with the microorganisms. The test 
compound solution (0.1 ml) was added to the cups, and the Petri 
dishes were subsequently incubated at 37 ᵒC for 48 h. MIC was 
defined as the lowest compound concentration preventing visible 
bacterial growth [16]. 
RESULTS AND DISCUSSION 
Chemistry 
The starting compound 7-hydroxy-4-methylcoumarin (I) was 
prepared as reported in the literature via Pechmann-Duisburg 
reaction [17]. Then the 8-acetylcoumarin derivative (II) was 
prepared by acetylation of the 7-hydroxy group with acetic 
anhydride [18] followed by Fries rearrangement using anhydrous 
AlCl3 [19]. To study the effect of alkylation of the 7-hydroxyl group 
on antimicrobial activity, the 7-ethoxy (IIIa), 7-allyloxy (IIIb), and 7-
butyloxy (IIIc) derivatives were prepared using the appropriate 
alkyl halide in dry acetone [20]. The 7-hydroxy (II) and the 7-
alkoxy derivatives (IIIa-IIIc) were then treated with hydrazine 
hydrate to yield the hydrazones (IV and Va-Vc) [21, 22], that 
reacted with different isothiocyanates to give coumarin-
thiosemicarbazones (VI-IX) in good yields [23]. Coumarin-
thiazolidine-4-ones (X-XIII) were formed by cyclizing the 
thiosemicarbazone (VI-IX) with chloroacetic acid, freshly fused 
sodium acetate in absolute ethanol, while the thiazolidin-4-one-
5-carboxylix acid ethyl ester derivatives (XIV-XVII) were 
prepared from intermediates (VI-IX) through cyclization with 
diethyl bromo malonate in refluxing absolute ethanol in the 
presence of fused sodium acetate [24].  
The synthetic pathways are outlined in scheme 1 and 2. The 
structures of the synthesized compounds were confirmed by 
spectral data and elemental analysis, and they were in full 




































VII,  R= Ethyl , a; R1= cyclohexyl, b; R1= phenyl, c; R1= p.methoxyphenyl 
VIII, R= Allyl,  a; R1= cyclohexyl, b; R1= benzyl, c; R1= p.methoxyphenyl 












Scheme 1: Reagent and conditions: a) acetic anhydride, reflux; 
b) Aluminum Chloride, fusion, 2 h, from 120 to 175 ᵒC; c) 
appropriate Alkyl halide, anhydrous K2CO3 in dry acetone, and 
reflux; d) Hydrazine hydrate, ethanol, and reflux; e) 
appropriate isothiocyanate derivatives, ethanol, and reflux 
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Xa,b;      R= H        
XIa-c;    R= Ethyl
XIIa-c;   R= Allyl
XIIIa, b; R= Butyl
XIVa, b;  R= H
XVa-c;    R= Ethyl
XVIa, c;  R= Allyl
XVIIa, b; R= Butyl
O
VIa, b;    R= H, 
VIIa-c;   R= Ethyl
VIIIa-c; R=  Allyl
IXa, b;   R=  Butyl
f
g
Scheme 2: Reagent and conditions: f) Chloroacetic acid and 
fused sodium acetate, ethanol, and reflux; g) diethyl bromo 
malonate and fused sodium acetate, ethanol, and reflux 
 
Antimicrobial activity 
The results (table 1) showed that compounds VIb, Xb, XIVb, XVa and 
XVc possessed strong inhibitory activity against S. aureus compared 
to the reference leads listed in table 2. While, compounds VIIa, VIIIa, 
IXa, IXb, and XIVa have moderate activity compared to the reference 
compound tobramycin. Compounds XIII and XIVb have fair to 
moderate activity against B. subtilis. The synthesized compounds 
had no activity on the Gram-negative strains used. The active 
compounds Xb, XIVb, XVa, and XVc showed activity against C. 
albicans beside the antibacterial activity which was better than lead 
7 that had only antifungal activity with MIC value of 0.1µg/ml.  
Compounds VIb, Xb, XIVb, and XVc, showed better inhibitory activity 
in terms of lower MIC values (0.19-0.36 µg/ml) than the lead drug 
bearing the same nucleus novobiocin 1 (MIC= 1 µg/ml). Novobiocin 
is known for its potent inhibitory activity against S. aureus especially 
methicillin-resistant strains through DNA-gyrase inhibition. Thus, 
the newly synthesized compounds represent promising antibacterial 
agents, especially against this strain.  
By comparing the minimum inhibitory concentration (MIC) (table 3) 
of the active compounds VIb, Xb, XIVb, and XVc to tobramycin (MIC= 
2 µg/ml) and novobiocin (MIC= 1 µg/ml), they gave better values 
ranging from 0.195-0.390 µg/ml; which were also better values 
reported for lead 5 (MIC= 25 µg/ml) and lead 6 (MIC= 10 µg/ml). 
Among the thiosemicarbazone series VI-IX, the 7-hydroxy derivative 
VIb with benzoyl group at N4 of thiosemicarbazone was the most 
active with a zone of inhibition value of 35 mm and MIC value of 
0.195µg/ml. This result showed the importance of the free hydroxyl 
group at this position. On the other hand, the 7-alkoxy derivatives 
VIIa, VIIIa, and IXa were moderately active when compared to their 
aromatic analogs VIIb, VIIc, VIIIb, and VIIIc.  
In thiazolidine-4-one series X-XIII, compound Xb had stronger 
activity against S. aureus with MIC value of 0.390 µg/ml and showed 
weak activity against C. albicans, which may be attributed to the 
presence of thiazolidine-4-one ring when compared to its precursor 
compound VIb. Also, compound XIIIa showed slight activity against 
B. subtilis. While, in the thiazolidine-4-one-5-carboxylic acid ethyl 
ester series XIV-XVII, compounds XIVb, XVa, XVc had strong 
antibacterial activity when compared to their analogs (Xb), (VIIa, 
XIa), and (VIIc, XIc) respectively. Compound XIVa possessed 
moderate activity over compound VIa, and Xa which may be 
attributed to the 5-carboxylic acid ethyl ester on the thiazolidine-4-
one ring. In summary, it was evidenced that the presence of free 7-
hydroxyl group on 4-methycoumarin ring was very important for 
activity. The hybridization with thiosemicarbazone substituted with 
benzoyl moiety as in compound VIb or thiazolidine-4-one-5-
carboxylic acid ethyl ester as in compound XIVb gave rise to 
promising antimicrobial agents. 
 























Compound number R R1 R2 S. aureus B. subtilis C. albicans 
Tobramycin    21 mm ND ND 
 VIb H Benzoyl   35 mm - - 
VIIa Ethyl Cyclohexyl  10 mm - - 
VIIIa Allyl Cyclohexyl  14 mm - - 
IXa Butyl Ethyl  14 mm ND ND 
IXb Butyl Benzyl  10 mm ND ND 
Xb H Benzoyl H 30 mm - 8 mm 
XIIIa Butyl Ethyl H - 8 mm - 
XIVa H Benzyl COOC2H5 13 mm - - 
XIVb H Benzoyl COOC2H5 30 mm 12 mm 14 mm 
XVa Ethyl Cyclohexyl COOC2H5 19 mm - 9 mm 
XVc Ethyl P. methoxyphenyl COOC2H5 22 mm - 11 mm 
*Presented are the mean of 3 separate experiments; Errors are in the range±10% of the reported values. Inactive: inhibition zone<5 mm; slightly 
active: inhibition zone = 5-10 mm; moderately active: inhibition zone = 10-15 mm; highly active: inhibition zone>15 mm, **ND; not determined, *** 
S. aureus: Staphylococcus aureus, B. subtilis: Bacillus subtilis, C. albicans: Candida albicans 
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Table 2: Comparison of the activity of the new active compounds to previously reported leads against Staphylococcus aureus 









8 [25]  





























18 mm 85% 
VIb (this work) 35 mm 166% 
Xb (this work) 30 mm 142% 
XIVb (this work) 30 mm 142% 
XVc (this work) 22 mm 104% 
* % Inhibition= zone of inhibition of compounds in mm/mm of tobramycin*100 [25] 
 
Table 3: The mean* MIC (µg/ml) values of the active compounds VIb, Xb, XIVb, and XVc and the comparison of these values to the reported 
MIC values of compounds having similar pharmacophores 
Compound number Minimum inhibitory concentration MIC (µg/ml) 
Tobramycin 2 
Novobiocin 1 [27] 
5 25 [12] 
6 10 [13, 14] 





* Presented are the mean of 3 separate experiments; errors are in the range±10% of the reported values. MIC mean values for compounds with a 
zone of inhibition>20 mm was determined. 
 
CONCLUSION 
The novel series of 4-methylcoumarin bearing thiosemicarbazone 
moiety (VI-IX) and the series having thiazolidine-4-one (X-XVII) 
were synthesized, and their antimicrobial activity was evaluated. 
These novel coumarin derivatives showed potential activity against 
Gram-positive Staphylococcus aureus especially these with a free 7-
hydroxy group (VIb, Xb, XIVb); that emphasize the importance of 
this position for antibacterial activity and compounds XIVa, XVa, and 
XVc with 5-carboxylic acid ethyl ester group on thiazolodin-4-one 
ring showed enhanced potency than their parent compounds. Hence, 
it can be concluded that these novel compounds are potential 
antibacterial agents better than the reference compounds and 
represent promising leads for further optimization and clinical 
studies. 
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